These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 20546778)

  • 1. Recent therapeutic approaches to platelet activation in coronary artery disease.
    Tousoulis D; Paroutoglou IP; Papageorgiou N; Charakida M; Stefanadis C
    Pharmacol Ther; 2010 Aug; 127(2):108-20. PubMed ID: 20546778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanisms of platelet activation and development of antiplatelet agents].
    Cazenave JP; Gachet C; Lanza F
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1501-6. PubMed ID: 9092410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor.
    Hoylaerts MF
    Verh K Acad Geneeskd Belg; 1997; 59(3):161-83. PubMed ID: 9490916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral antiplatelet agents in ACS: from pharmacology to clinical differences.
    Agewall S; Badimon L; Drouet L; Eschenhagen T; Husted S; Simon T; Steg G
    Fundam Clin Pharmacol; 2011 Oct; 25(5):564-71. PubMed ID: 21077944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
    Wiviott SD
    Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
    Geisler T; Kapp M; Göhring-Frischholz K; Daub K; Dösch C; Bigalke B; Langer H; Herdeg C; Gawaz M
    Heart; 2008 Jun; 94(6):743-7. PubMed ID: 17567647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel antiplatelet strategies in acute coronary syndromes.
    Sabatine MS
    Cleve Clin J Med; 2009 Apr; 76 Suppl 1():S8-15. PubMed ID: 19332592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
    Dropinski J; Musial J; Jakiela B; Wegrzyn W; Sanak M; Szczeklik A
    Thromb Haemost; 2005 Dec; 94(6):1300-5. PubMed ID: 16411409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
    Anderson SD; Shah NK; Yim J; Epstein BJ
    Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management.
    Cowley MJ; Kuritzky L
    Curr Med Res Opin; 2009 Jun; 25(6):1477-90. PubMed ID: 19419337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. eNOS gene influences platelet phenotype in acute coronary syndrome patients on dual antiplatelet treatment.
    Fatini C; Sticchi E; Bolli P; Marcucci R; Giusti B; Paniccia R; Gori AM; Gensini GF; Abbate R
    Platelets; 2009 Dec; 20(8):548-54. PubMed ID: 19891529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPIbalpha-selective activation of platelets induces platelet signaling events comparable to GPVI activation events.
    Gardiner EE; Arthur JF; Shen Y; Karunakaran D; Moore LA; Am Esch JS; Andrews RK; Berndt MC
    Platelets; 2010; 21(4):244-52. PubMed ID: 20367574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thrombocyte receptors: current views and therapeutic options].
    Peters RJ; Moons AH; Büller HR
    Ned Tijdschr Geneeskd; 1999 Sep; 143(39):1952-7. PubMed ID: 10526614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet activation and progression to complications.
    Kereiakes DJ; Michelson AD
    Rev Cardiovasc Med; 2006; 7(2):75-81. PubMed ID: 16915126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
    Cuisset T; Hamilos M; Delrue M; Frère C; Verhamme K; Bartunek J; Saut N; Bonnet JL; Eijgelsheim M; Wijns W; Alessi MC; Barbato E
    Thromb Haemost; 2010 Apr; 103(4):774-9. PubMed ID: 20135061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetics of antiplatelet drug resistance.
    Feher G; Feher A; Pusch G; Lupkovics G; Szapary L; Papp E
    Clin Genet; 2009 Jan; 75(1):1-18. PubMed ID: 19067731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.